X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (137) 137
index medicus (137) 137
oncology (83) 83
melanoma (73) 73
female (72) 72
male (67) 67
middle aged (59) 59
aged (55) 55
dermatology (49) 49
adult (46) 46
melanoma - drug therapy (43) 43
cancer (42) 42
skin neoplasms - pathology (39) 39
melanoma - pathology (36) 36
metastasis (35) 35
skin neoplasms - drug therapy (35) 35
care and treatment (31) 31
ipilimumab (30) 30
skin (30) 30
aged, 80 and over (28) 28
survival (28) 28
metastatic melanoma (27) 27
skin cancer (26) 26
treatment outcome (26) 26
antineoplastic agents - therapeutic use (25) 25
analysis (24) 24
immunology (23) 23
prognosis (23) 23
retrospective studies (23) 23
melanoma - genetics (22) 22
mutation (22) 22
tumors (22) 22
histamine (20) 20
immunotherapy (20) 20
melanoma - mortality (20) 20
melanoma - secondary (20) 20
nivolumab (20) 20
metastases (19) 19
patients (19) 19
abridged index medicus (18) 18
medical colleges (17) 17
neoplasm staging (17) 17
hematology, oncology and palliative medicine (16) 16
clinical trials (15) 15
malignant-melanoma (15) 15
pembrolizumab (15) 15
skin neoplasms - mortality (15) 15
skin neoplasms - therapy (15) 15
therapy (15) 15
young adult (15) 15
antineoplastic agents - adverse effects (14) 14
disease-free survival (14) 14
lymphatic metastasis (14) 14
open-label (14) 14
proto-oncogene proteins b-raf - antagonists & inhibitors (14) 14
receptors, histamine h4 (14) 14
skin neoplasms - genetics (14) 14
dendritic cells (13) 13
diagnosis (13) 13
kaplan-meier estimate (13) 13
medical research (13) 13
melanoma - therapy (13) 13
vemurafenib (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
atopic-dermatitis (12) 12
cutaneous melanoma (12) 12
expression (12) 12
h-4 receptor (12) 12
mutations (12) 12
proto-oncogene proteins b-raf - genetics (12) 12
survival rate (12) 12
animals (11) 11
antibodies, monoclonal - adverse effects (11) 11
cell biology (11) 11
chemotherapy (11) 11
dendritic cells - immunology (11) 11
drug therapy (11) 11
neoplasm metastasis (11) 11
sentinel lymph node biopsy (11) 11
antibodies, monoclonal - therapeutic use (10) 10
antineoplastic agents - administration & dosage (10) 10
management (10) 10
medicine, research & experimental (10) 10
safety (10) 10
allergy (9) 9
braf (9) 9
cell lung-cancer (9) 9
cells, cultured (9) 9
complications and side effects (9) 9
dabrafenib (9) 9
follow-up studies (9) 9
lymph nodes - pathology (9) 9
medicine & public health (9) 9
mice (9) 9
protein kinase inhibitors - therapeutic use (9) 9
psoriasis (9) 9
radiotherapy (9) 9
receptors, histamine - metabolism (9) 9
sentinel lymph node (9) 9
untreated melanoma (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 08/2018, Volume 16, Issue 8, pp. 1063 - 1064
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 08/2018, Volume 16, Issue 8, pp. 1063 - 1064
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 08/2018, Volume 16, Issue 8, pp. 1063 - 1064
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Journal Article
JDDG, ISSN 1610-0379, 05/2015, Volume 13, Issue 5, p. 485
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 05/2015, Volume 13, Issue 5, pp. 485 - 487
Journal Article
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, ISSN 1610-0379, 05/2015, Volume 13, Issue 5, pp. 485 - 487
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 716 - 728
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 435 - 445
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 733 - 740
Summary Background Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | TRIAL | KINASE KINASE-1/2 INHIBITOR | MULTICENTER | ONCOLOGY | ORAL MEK INHIBITOR | IMPROVED SURVIVAL | INHIBITOR AZD6244 ARRY-142886 | OPEN-LABEL | MUTATIONS | VEMURAFENIB | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Skin Neoplasms - enzymology | Benzimidazoles - administration & dosage | Time Factors | DNA Mutational Analysis | Brazil | Proto-Oncogene Proteins B-raf - metabolism | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Neoplasms, Unknown Primary - genetics | Europe | Logistic Models | Antineoplastic Agents, Alkylating - therapeutic use | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Melanoma - mortality | Dacarbazine - therapeutic use | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Melanoma - enzymology | Neoplasms, Unknown Primary - enzymology | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | Neoplasms, Unknown Primary - drug therapy | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Neoplasms, Unknown Primary - mortality | Melanoma - secondary | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasms, Unknown Primary - pathology | Care and treatment | Chemotherapy | Gene mutations | Analysis | Melanoma | Metastasis | Cancer | Index Medicus
Journal Article
01/2019, 1st ed. 2019, ISBN 3319912283, 248
This is the first book that analyses the future raw materials supply from the demand side of a society that chiefly relies on renewable energies, which is of... 
Power resources | Energy Materials | Earth Sciences | Biogeosciences | Economic Geology | Renewable and Green Energy
eBook
JDDG - Journal of the German Society of Dermatology, ISSN 1610-0379, 03/2017, Volume 15, Issue 3, pp. 350 - 352
Journal Article
Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 03/2009, Volume 123, Issue 3, pp. 619 - 625
Background: Histamine influences T-cell reactions via histamine receptors 1 and 2. The histamine receptor 4 (H R) is the most recently identified histamine... 
H | Histamine | receptor | T cells | IL-31 | Studies | Proteins | Signal transduction | Lymphocytes | Ligands | Regulation | Blood banks | Dermatitis | Experiments | Allergies | Chemokines | Immune system
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
The Lancet Oncology, ISSN 1470-2045, 05/2018, Volume 19, Issue 5, pp. 603 - 615
Journal Article